Page last updated: 2024-08-17

dichloroacetic acid and Cancer of Head

dichloroacetic acid has been researched along with Cancer of Head in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (66.67)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Black, LJ; Bleeker, JS; Dib, EG; Ellison, CA; Geeraerts, LH; Jensen, AW; Lee, JH; Lohr, MM; Mazurczak, M; McGraw, SC; Miskimins, WK; Powell, SF; Puumala, SE; Reed, VJ; Spanos, WC; Tinguely, M	1
Jang, HJ; Kim, EH; Kwon, M; Park, JY; Roh, JL	1
Fan, Z; Li, X; Lu, H; Lu, Y; Qiu, S	1

Trials

1 trial(s) available for dichloroacetic acid and Cancer of Head

Article	Year
Phase II study of dichloroacetate, an inhibitor of pyruvate dehydrogenase, in combination with chemoradiotherapy for unresected, locally advanced head and neck squamous cell carcinoma. Investigational new drugs, 2022, Volume: 40, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Dichloroacetic Acid; Head and Neck Neoplasms; Humans; Oxidoreductases; Pyruvates; Squamous Cell Carcinoma of Head and Neck	2022

Article

Year

Phase II study of dichloroacetate, an inhibitor of pyruvate dehydrogenase, in combination with chemoradiotherapy for unresected, locally advanced head and neck squamous cell carcinoma.

Investigational new drugs, 2022, Volume: 40, Issue:3

Topics: Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Dichloroacetic Acid; Head and Neck Neoplasms; Humans; Oxidoreductases; Pyruvates; Squamous Cell Carcinoma of Head and Neck

2022

Other Studies

2 other study(ies) available for dichloroacetic acid and Cancer of Head

Article	Year
Activation of mitochondrial oxidation by PDK2 inhibition reverses cisplatin resistance in head and neck cancer. Cancer letters, 2016, Feb-01, Volume: 371, Issue:1 Topics: Animals; Antineoplastic Agents; Antioxidants; Apoptosis; Caspase Inhibitors; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Cisplatin; Dichloroacetic Acid; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Glycolysis; Head and Neck Neoplasms; Humans; Male; Membrane Potential, Mitochondrial; Mice, Inbred BALB C; Mice, Nude; Mitochondria; Oxidation-Reduction; Protein Serine-Threonine Kinases; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Reactive Oxygen Species; RNA Interference; Time Factors; Transfection; Xenograft Model Antitumor Assays	2016
ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis. Cancer letters, 2016, 10-10, Volume: 381, Issue:1 Topics: Amino Acid Transport System ASC; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Dichloroacetic Acid; Down-Regulation; Endocytosis; ErbB Receptors; Gefitinib; Glutamine; Glutathione; Head and Neck Neoplasms; Humans; Minor Histocompatibility Antigens; Oxidative Stress; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Quinazolines; Reactive Oxygen Species; RNA Interference; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Time Factors; Transfection	2016

Article

Year

Activation of mitochondrial oxidation by PDK2 inhibition reverses cisplatin resistance in head and neck cancer.

Cancer letters, 2016, Feb-01, Volume: 371, Issue:1

Topics: Animals; Antineoplastic Agents; Antioxidants; Apoptosis; Caspase Inhibitors; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Cisplatin; Dichloroacetic Acid; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Glycolysis; Head and Neck Neoplasms; Humans; Male; Membrane Potential, Mitochondrial; Mice, Inbred BALB C; Mice, Nude; Mitochondria; Oxidation-Reduction; Protein Serine-Threonine Kinases; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Reactive Oxygen Species; RNA Interference; Time Factors; Transfection; Xenograft Model Antitumor Assays

2016

ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis.

Cancer letters, 2016, 10-10, Volume: 381, Issue:1

Topics: Amino Acid Transport System ASC; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Dichloroacetic Acid; Down-Regulation; Endocytosis; ErbB Receptors; Gefitinib; Glutamine; Glutathione; Head and Neck Neoplasms; Humans; Minor Histocompatibility Antigens; Oxidative Stress; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Quinazolines; Reactive Oxygen Species; RNA Interference; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Time Factors; Transfection

2016